Medivive review

What it is

Medivive is a US telehealth service running several programs on one account: compounded GLP-1 weight loss, testosterone replacement therapy for men, hormone replacement therapy for women, NAD⁺ and peptide longevity medicine, plus erectile dysfunction, hair and lab testing. Its longevity page names NAD⁺ therapy alongside BPC-157 and CJC-1295/ipamorelin as examples of the peptides it prescribes where clinically appropriate. It states providers are licensed in all 50 US states, that no insurance is required, that medication is compounded by a licensed US pharmacy and delivered to you, and that care is available in English and Spanish.

How it works

An AI-guided intake matches you to candidate treatments from what the site calls a live clinical catalog and then hands you to a licensed provider for review — an unusual front end that is worth understanding before you start, because the catalog match happens before a clinician is involved. Lab work is built into the model as an at-home collection rather than a lab trip, which lowers a real barrier. The strongest thing here is specificity: naming NAD⁺, BPC-157 and CJC-1295/ipamorelin, and attaching a clinical-indication condition to each, is better disclosure than the "peptide therapy" placeholder most competitors run. Its education pages also carry FDA boxed-warning language verbatim, which is a good-faith signal. Against that, the corporate layer is thin: no LLC or corporation is disclosed on the site or in the privacy policy, no compounding pharmacy is named, no LegitScript or PCAB certification is displayed, and the 50-state claim is about provider licensure rather than an enumerated availability list. The site also displays its own aggregate patient rating; we do not repeat those numbers.

Pricing transparency

There is no NAD⁺ price, and we are not going to invent one from the figure that does exist. Medivive publishes a single number, an all-in monthly rate described as covering medication and care with no membership fee, and its own pricing block does not name a molecule against it — the service covers both compounded semaglutide and tirzepatide and the figure sits in the weight-loss flow. Assigning that number to NAD⁺ would be fabrication, so this card carries no price. Everything else is disclosed only after the AI intake and, where used, the at-home lab draw. Before you begin, ask what NAD⁺ costs at the route and dose you would be prescribed, whether the lab draw is billed separately, whether shipping is free, and what a peptide protocol costs on top of any program fee — the site describes delivery without stating that it is free, which is a distinction worth pinning down.

Branded vs compounded

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Medivive states that its medication is compounded by a licensed US pharmacy but does not name it, and compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. On the evidence the longevity menu splits three ways and none of it is equivalent. Injected NAD⁺ has no controlled human outcome trials; the one human intravenous study was a pharmacokinetic pilot showing infused NAD⁺ clears from plasma quickly, and the forms with human trial data are the oral precursors NR and NMN, which reliably raise blood NAD⁺ — a biomarker rather than a clinical outcome. BPC-157 is a synthetic pentadecapeptide derived from a gastric-juice protein with an interesting animal literature on tendon, ligament and gut-lining repair and essentially no controlled human outcome trials. CJC-1295 with ipamorelin is a growth-hormone secretagogue pairing that works through your own pituitary — a real mechanism with thin long-term human outcome data. Testosterone replacement, on the other side of the service, is the one therapy here with a large randomised safety base, and it suppresses natural production and fertility and requires ongoing monitoring. Individual results vary.

Pros and watch-outs

The evidence behind what Medivive prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• NAD+ precursors (NR and NMN): what the human trials actually show

  They raise NAD+ and look safe short-term — but human evidence is surrogate-marker level, and no trial shows they extend healthspan.

• BPC 157: what the evidence actually shows (and what it doesn't)

  The 'healing peptide' has a deep rodent literature and almost no human data. A straight read of where the science stands.

• Ipamorelin & CJC-1295: the honest evidence on GH secretagogue peptides

  They reliably raise growth hormone — that part is real. The muscle, fat-loss and anti-aging claims are not supported by human outcome data. A straight read.

• TRT: what testosterone therapy is actually proven to do

  An FDA-approved therapy for diagnosed hypogonadism — with real but moderate benefits (sexual function, mood; not vitality), cardiovascular non-inferiority in TRAVERSE, and a real fertility trade-off.

How Medivive compares

A few alternatives worth a look, depending on what you’re optimizing for.

• MEMeto

  NAD⁺ buyers who want bloodwork behind the prescription and the price published in advance

  See Meto →
• MAMaves

  NAD⁺ at a published all-in monthly price across all 50 states

  See Maves →
• LULumora

  A certified 50-state NAD⁺ program if you will complete an assessment before seeing anything

  See Lumora →